Hydroxychloroquine (Plaquenil) Dosing and Monitoring
Dose hydroxychloroquine at ≤5.0 mg/kg based on actual body weight (not ideal body weight), perform baseline ophthalmologic examination within the first year, and begin annual retinal screening after 5 years of use unless major risk factors are present. 1, 2, 3
Dosing Strategy
Weight-Based Calculation
- Calculate dose using actual (real) body weight, NOT ideal body weight 1, 2
- Maximum daily dose: ≤5.0 mg/kg of actual body weight 1, 2
- Typical starting dose: 200 mg daily (approximately 3.0-3.5 mg/kg/day for most patients) 4
- For chloroquine: ≤2.3 mg/kg/day actual body weight 1
The shift to actual body weight dosing is critical—previous recommendations using ideal body weight resulted in overdosing thin patients and underdosing heavier patients. Risk data show that dosing based on actual weight provides consistent safety across BMI ranges from 15-35 kg/m² 1.
Practical Dosing Adjustments
- Hydroxychloroquine tablets: 200 mg (can split or skip days to achieve intermediate doses)
- For doses between standard tablets, skip one tablet on specific days weekly—blood levels stabilize over weeks, so variable dosing averages out 2
- Doses >5.0 mg/kg dramatically increase retinopathy risk to 10% at 10 years (vs <2% at recommended doses) 1
Baseline Assessment (Within First Year)
Perform comprehensive ophthalmologic examination including: 2, 3
- Best corrected distance visual acuity (BCVA)
- Automated threshold visual field testing of central 10 degrees (central 24 degrees for Asian patients due to pericentral toxicity pattern) 2, 3, 5
- Spectral-domain optical coherence tomography (SD-OCT)
- Fundus examination
Ongoing Monitoring Schedule
Standard Risk Patients
- Defer annual ophthalmologic screening until after 5 years of continuous use 2, 3
- After 5 years: Annual screening with automated visual fields AND SD-OCT 2
- Check dosage relative to weight at every visit 2
High-Risk Patients (Begin Annual Screening Earlier)
Major risk factors requiring earlier/more frequent screening: 1, 2
- Daily dose >5.0 mg/kg actual body weight
- Renal insufficiency (subnormal glomerular filtration rate—drug is renally cleared, increasing systemic levels) 1, 2
- Concomitant tamoxifen use (independently retinotoxic and increases hydroxychloroquine retinopathy risk) 1, 2
- Pre-existing macular disease (may increase susceptibility and interfere with screening interpretation) 2
For high-risk patients: Begin annual screening immediately or within 1-2 years rather than waiting 5 years 2.
Screening Modalities
Primary recommended tests (use both): 2, 6
- Automated visual field testing (10-2 pattern for non-Asian; 30-2 or 24-2 for Asian patients)
- Spectral-domain OCT (detects early photoreceptor layer thinning before funduscopic changes)
Additional tests when indicated:
- Fundus autofluorescence (shows RPE changes)
- Multifocal electroretinography (functional testing)
Critical Risk Considerations
Duration-Dependent Risk
Even at recommended doses, retinopathy risk increases with duration: 1, 5
- <5 years: <2% risk
- 10 years: ~4% risk
- 20 years: ~20% risk
Renal Disease Adjustment
Patients with renal insufficiency require dose reduction and closer monitoring due to reduced drug clearance 1, 2. Current data don't support precise reduction formulas—discuss risk-benefit with patient and consider more frequent screening.
Cardiac Monitoring
While retinopathy receives primary focus, monitor for cardiomyopathy signs (atrioventricular block, bundle branch block, biventricular hypertrophy) and QT prolongation 3. Consider baseline and periodic ECGs, particularly in patients with cardiac risk factors.
Key Clinical Pitfalls
- Do NOT use ideal body weight—this outdated approach causes dosing errors 1, 2
- Do NOT stop screening after 5 years—risk continues increasing with duration 1, 5
- Do NOT delay screening in high-risk patients—renal disease and tamoxifen use require earlier monitoring 1, 2
- For Asian patients, screen wider retinal field (24 degrees vs 10 degrees)—they develop pericentral/extramacular toxicity patterns 2, 3, 5
- Retinopathy is irreversible and may progress after stopping drug—early detection is critical 2
When to Discontinue
Stop hydroxychloroquine immediately if: 2, 3
- Definitive retinal toxicity detected on screening (verified with repeat testing or multiple modalities)
- Signs of cardiomyopathy (conduction abnormalities, biventricular hypertrophy)
- Life-threatening cardiac arrhythmias
Do NOT stop for borderline or uncertain findings—repeat testing and use multiple modalities to confirm before discontinuing this valuable medication 2.